

**Dual use life science research DUR/C Dialogue with Academies and Councils
Videoconference using the Zoom platform
July 6, 2020, 14:00-16:00 (CEST)**

PROVISIONAL AGENDA

Meeting objectives

- To present WHO Health Foresight function and DUR/C activities;
- To gather and exchange different stakeholder perspectives on approaches to DUR/C and to raise awareness on DUR/C issues among different stakeholder groups;
- To identify critical issues in DUR/C from the perspective of academies and councils;
- To highlight lessons learned from past experiences on addressing issues and concerns in DUR/C; and
- To identify key priority areas for action and appropriate areas for collaboration with different stakeholder groups.

Time	Monday, July 6, 2020
13:55-14:00	Zoom opens
14:00-14:30	Session 1: Welcome and meeting objectives
	Moderator: <i>Catherine Mulholland, Research for Health Department - Science Division, WHO, Switzerland</i>
14:00-14:15	Welcome Introductions How to participate Meeting objectives
14:15-14:30	Presentation of the WHO Foresight function and its links to DUR/C activities <i>Anna Laura Ross, Unit Head, Emerging Technologies, Research Prioritisation and Support, Research for Health Department - Science Division, WHO, Switzerland</i>
14:30-15:10	Session 2: Key activities and challenges in DUR/C
	Moderator: <i>Anna Laura Ross, WHO</i>
	Objectives of Session 2: Overview of key activities taken by academies and councils to address dual use life science research issues; discuss main lessons learned to date and analyze key challenges. Kick off poll on dual use life science research using the survey on Zoom

	<p>Topics for discussion:</p> <ol style="list-style-type: none"> 1. What have been the key actions taken by some academies and councils to address dual use life science research issues (DUR/C)? 2. What key actions have been successful? What does not work and why? What have been the main lessons learned to date? <p>Open discussion</p>
15:10-15:50	Session 3: Identification of priority actions and actors
	Moderator: <i>Emmanuelle Tuerlings, Consultant, WHO, Switzerland</i>
	<p>Objectives of Session 3: To identify major key actions needed to address challenges identified, to set priorities for action and identify respective roles</p> <p>Topics for discussion:</p> <ol style="list-style-type: none"> 1. What do you think are the most pressing actions to be taken in DUR/C and in what time frame? 2. Who needs to be involved in these actions? 3. What are the challenges we may face in implementing these actions? <p>Open discussion</p>
15:50-16:00	Session 4: Wrap up and next steps
	Moderator: <i>Catherine Mulholland, WHO</i>
	<p>Key takeaways</p> <p>Next steps <i>Anna Laura Ross, WHO</i></p>